COX.PA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2023 @ 23:35):

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health...

Stats
今日成交量	246 141
平均成交量	196 980
市值	29.04M
EPS	€0 ( 2024-04-17 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.456
ATR14	€0.0560 (9.49%)

音量相关性

長: -0.11 (neutral)

短: -0.95 (very strong negative)

Signal:(45.399) Neutral

Nicox SA 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Nicox SA 相关性 - 货币/商品

-0.85
( strong negative )

-0.53
( weak negative )

0.00
( neutral )

-0.46
( neutral )

0.84
( strong )

Nicox SA 财务报表

Annual	2022
营收:	€5.24M
毛利润:	€3.27M (62.40 %)
EPS:	€0

FY	2022
营收:	€5.24M
毛利润:	€3.27M (62.40 %)
EPS:	€0

FY	2021
营收:	€8.58M
毛利润:	€7.23M (84.27 %)
EPS:	€-1.170

FY	2020
营收:	€14.42M
毛利润:	€12.91M (89.49 %)
EPS:	€-0.540

Financial Reports:

No articles found.

Nicox SA

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.